NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial
PHASE2
VALENTINE is a parallel, non-comparative, three-arm, randomized 1:2:2 open-...
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
PHASE1
This study includes a Dose Escalation Part to identify the recommended comb...
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
PHASE1
ICARUS-BREAST02 is an open-label, multicenter, phase 1b/2, platform study t...